Clinical Trials Using Liposomal Cytarabine
Clinical trials are research studies that involve people. The clinical trials on this list are studying Liposomal Cytarabine. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Intensive Combination Chemotherapy and Liposomal Cytarabine in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This partially randomized phase II trial studies how well intensive combination chemotherapy and liposomal cytarabine (a form of the anticancer drug cytarabine that is contained inside very tiny, fat-like particles) work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as daunorubicin hydrochloride, cyclophosphamide, vincristine sulfate, prednisone, leucovorin calcium, cytarabine, etoposide, and liposomal cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Biological therapies, such as mercaptopurine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Pegaspargase, methotrexate, dasatinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with, rituximab, mercaptopurine, pegaspargase, methotrexate, dasatinib and imatinib mesylate may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic lymphoma.
Location: 4 locations
Treatment for Advanced B-Cell Lymphoma
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy backbone (Immunochemotherapy).
Location: 2 locations